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ABSTRACT 20 
 21 
TP53 truncating mutations are common in human tumors and are thought to give 22 
rise to p53-null alleles. Here, we show that TP53 exon-6 truncating mutations 23 
occur at higher than expected frequencies and produce proteins that lack 24 
canonical p53 tumor suppressor activities but promote cancer cell proliferation, 25 
survival, and metastasis. Functionally and molecularly, these p53 mutants 26 
resemble the naturally occurring alternative p53 splice variant, p53-psi. 27 
Accordingly, these mutants can localize to mitochondria where they promote 28 
tumor phenotypes by binding and activating the mitochondria inner pore 29 
permeability regulator, Cyclophilin D (CypD). Together, our studies reveal that 30 
TP53 exon-6 truncating mutations, contrary to current beliefs, act beyond p53 loss 31 
to promote tumorigenesis, and could inform the development of strategies to 32 
target cancers driven by these prevalent mutations. 33 
34 
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INTRODUCTION 35 
 36 
The International Cancer Genome Consortium has recognized that the TP53 gene is the 37 
most frequently mutated gene in human cancer (Hollstein et al., 1991; Olivier et al., 38 
2010). Genetic studies show that, in most tumors, TP53 point mutations co-occur with 39 
the loss of one copy of the TP53 gene (LOH) due to deletions in chromosome 17 where 40 
the TP53 locus is located (Baker et al., 1989; Menon et al., 1990; Olivier et al., 2010; 41 
Rivlin et al., 2011; Liu et al., 2016). Consistent with these observations and the two-hit 42 
hypothesis proposed by A.G. Knudson, experimental evidences have led to the 43 
description of TP53 as a tumor suppressor gene (Knudson, 1971; Baker et al., 1989; 44 
Finlay et al., 1989; Donehower et al., 1992).  45 
 46 
This simplistic vision has been challanged by recent studies spurred by the observation 47 
that TP53 missense mutations do not have a uniform distribution; rather, they occur 48 
more frequently at specific residues (R175, G245, R248, R249, R273 and R282) often 49 
referred to as “hotspot” TP53 mutation sites (Petitjean et al. 2007; Brosh and Rotter, 50 
2009). The high frequency of these mutations led to the hypothesis that these hotspot 51 
mutations could not only result in loss of function activities, but also could confer an 52 
advantage of growth to cancer cells. Indeed, many lines of evidence have now 53 
demonstrated that certain p53 missense mutants could exhibit gain of function activities 54 
during tumorigenesis (Brosh and Rotter, 2009; Oren and Rotter, 2010). For instance, 55 
some of the gain of function mutations, including R175H, R248Q, R273H, resulted in an 56 
increase in cell invasion, cell migration, cell proliferation and anti-apoptosis in different 57 
in-vitro models (Muller and Vousden, 2014). Additionally, mice expressing TP53 R172H 58 
(human R175H) and R270H (human R273H) mutations manifest a broad spectrum of 59 
aggressive tumors that are more metastatic in nature when compared to p53-null mice 60 
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(Lang et al., 2004; Olive, Tuveson et al., 2004; Doyle et al., 2010). Though different gain 61 
of function mutants exhibit various pro-tumorigenic phenotypes, their mechanism of 62 
function mostly relies on alterations to the p53 transcription program (Freed-Pastor and 63 
Prives, 2012).   64 
 65 
In this study, we similarly report that certain TP53 truncating mutations promote 66 
tumorigenesis rather than halt it. In fact, we observed that TP53 exon-6 truncating 67 
mutations occur at higher than expected frequencies and, when ectopically expressed in 68 
cells, induce the acquisition of pro-metastatic features. In contrast to TP53 missense 69 
gain of function mutations, we found that TP53 exon-6 truncating mutations are 70 
necessary for cell survival in normal 2-D cell growing conditions. These TP53 truncating 71 
mutations also different from canonical p53 missense gain of function mutants in regards 72 
to their mode of action. As we have shown in this study, these p53 mutants lack 73 
transcriptional activity and, instead, have phenotypes that depend on their molecular and 74 
functional interactions with Cyclophilin D in the mitochondria. 75 
 76 
 Much like EGFR, ROS and ALK mutations have been candidates for precision 77 
medicine, the relatively frequent distribution of exon-6 TP53 truncating mutations in 78 
certain tumors, combined with the availability of CypD inhibitors, implies that these 79 
mutations may similarly be successfully targeted with precision medicine.  80 
 81 
  82 
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RESULTS  83 
 84 
TP53 exon-6 truncating mutations occur at a higher than expected frequency 85 
 86 
While the gain of function activity of p53 missense mutants has been studied extensively 87 
(Brosh and Rotter, 2009; Oren and Rotter, 2010), the biological effects of p53 nonsense 88 
mutants have yet to be explored.  89 
 90 
To address this, we first examined a panel of 22 sequencing studies, predominantly 91 
carried out by the Cancer Genome Atlas (TCGA) project and accessed using the cBio 92 
portal, referred to here as the “TCGA cohort” (Cerami et al., 2012). Studies were 93 
selected for inclusion on the basis of having more than 100 samples per tumor type and 94 
at least 10 tumors with TP53 mutations (Supplementary File 1). As shown in Figure 1A, 95 
it is evident that TP53 nonsense mutations are distributed non-randomly with increased 96 
frequency in correspondence to TP53 exon-6 (i.e. TP53 exon-6 nonsense). Interestingly, 97 
our analysis also indicated that nonsense mutations occur at sites distinct from those 98 
affected by missense mutations (Figure 1A). These findings were confirmed in an 99 
independent pan-cancer dataset of 3,797 cases, in which targeted sequencing was 100 
performed at Memorial Sloan Kettering Cancer Center (MSK-IMPACT, Cheng et al., 101 
2015), referred to here as the “MSKCC cohort” (Figure 1B).  102 
 103 
To determine the relative strength of selection pressure for nonsense and missense 104 
mutants, we calculated the number of theoretical changes (i.e., expected cases) and 105 
compared this value to the observed frequency of mutations. As indicated in Figure 1E, 106 
we found that in the case of missense mutations the relative expected frequency was 107 
0.34, while the relative observed frequency was 0.64, based on the analysis of the 108 
 6
TCGA cohort. This finding suggests that missense mutations are observed at a 109 
frequency that is 1.9 fold higher than expected. In the case of nonsense mutations, we 110 
observed a slight difference between the expected frequency (i.e., 0.054) and observed 111 
frequency (i.e., 0.084) of mutations. Interestingly, when we limited our analysis only to 112 
exon-6 nonsense mutations we found a 4-5 fold increase in the observed frequency 113 
compared to the expected frequency (Figures 1C, 1D and Figure 1- figure supplement 114 
1A). This finding indicates that nonsense mutations in exon-6 occur nearly 5 times more 115 
frequently than all TP53 mutations (p=3.869e-11) and 2-3 times more frequently than 116 
either missense mutations or nonsense mutations outside of exon-6 (p=3.71e-4 and 117 
p=8e-5, respectively). These results were confirmed in the MSKCC cohort (Figure 1D, 118 
1E and Figure 1- figure supplement 1B). 119 
 120 
In addition to nonsense mutations, frameshift and splice site mutations may produce 121 
truncated proteins. We found that even though nonsense mutations occur at a rate of 122 
13%, overall truncating mutations account for more than 25% of all TP53 mutations in 123 
both datasets examined (Figure 1- figure supplement 1). We also observed that the 124 
distribution of TP53 mutations differs in various tumor types, ranging from 7.3% to 94.9% 125 
in the case of multiple myeloma (MM) and ovarian serous cystadenocarcinoma (OVCA) 126 
respectively (Supplementary File 1). As for TP53 truncating mutations, their frequency of 127 
occurrence spans from 1.46% in MM to 27.53% in lung squamous cell carcinoma 128 
(LUSC). Notably, in pancreatic adenocarcinoma (PAAD), esophageal adenocarcinoma 129 
(ESAD), squamous cell carcinoma (ESCC), head and neck squamous cell carcinoma 130 
(HNSC), colorectal adenocarcinoma (COAD) and skin cutaneous melanoma (SKCM), 131 
the frequency of TP53 exon-6 truncating mutations was higher than 6% (Supplementary 132 
File 1).  133 
 134 
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Although the frequency of TP53 exon-6 truncating mutations followed the distribution of 135 
TP53 mutations in the majority of tumors examined, this was not always the case. This 136 
phenomenon is best exemplified by our observations of lung small cell carcinoma 137 
(LUSCC) wherein, despite the nearly ubiquitous presence of TP53 alterations, we found 138 
no exon-6 truncations (Figure 1F and Figure 1- figure supplement 3). 139 
 140 
Strikingly, in the MSKCC cohort, we found a statistically significant increase in the 141 
frequency of TP53 exon-6 truncating mutations in colorectal cancer (CRC) metastatic 142 
site tumors with respect to primary tumors (Figure 1G and Supplementary File 3). This is 143 
reminiscent of a previous study in which an analysis of colorectal cancers revealed an 144 
increased representation of TP53 exon-6 mutations in liver metastases (Miyaki et al., 145 
2002). Although we found an increase in In-Frame indel mutations in metastatic tumors 146 
compared to primary tumors, this increase was not deemed statistically significant as the 147 
number of primary tumors identified with mutations was very low (n=3 for primary and 148 
n=10 for metastasis).  149 
 150 
p53 exon-6 truncating mutants reprogram cells towards the acquisition of pro-151 
metastatic features 152 
 153 
In principle, a higher than expected occurrence of truncating mutations could be linked to 154 
a particular etiology, to variable nucleotides substitutions or to translation termination 155 
efficiency (Mort et al., 2008). On the other hand, and as has been demonstrated for gain 156 
of function TP53 mutations, the higher than expected frequency of TP53 exon-6 157 
truncating mutations could instead underlie a selective advantage during tumorigenesis 158 
(Muller and Vousden, 2014).  159 
 160 
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To test this hypothesis, we generated cell lines ectopically expressing multiple p53 C-161 
terminal truncated proteins mirroring the R213* and R196* exon-6 p53 truncating 162 
mutants, and compared their activities to p53 full length (i.e., p53-WT), a longer p53 163 
truncating mutant (G325*) and a shorter p53 truncating mutant (W146*) (Figures 2A, 2B 164 
and Figure 2- figure supplement 2).  165 
 166 
As is consistent with their lack of tumor suppressor activities, different p53 C-terminal 167 
truncating proteins ectopically expressed in a p53 homozygous deletion cell line (H1299) 168 
failed to decrease cell viability (Figure 2C). Yet, as shown in Figure 2, ectopic expression 169 
of TP53 exon-6 truncations in A549 cell line (lung cancer-derived epithelial line) induced 170 
changes in the morphological appearances of cells (Figure 2D) and the acquisition of 171 
mesenchymal-like features such as (i) the transition of filamentous actin from a cortical 172 
distribution to stress fibers formation (Figure 2D), (ii) decreased expression and 173 
localization of E-cadherin (Figures 2D and 2E), (iii) increased expression of vimentin, 174 
and (iv) increased expression of the master regulators of epithelial to mesenchymal 175 
transition (EMT): Slug, Snail and Zeb1 (Figure 2E) (Lamouille et al., 2014).  176 
 177 
Consistent with an EMT-like phenotype, cells expressing p53 exon-6 truncations were 178 
also characterized by increased motility (Figure 2F and Figure 2- figure supplement 1) 179 
and extra-cellular matrix invasion (Figure 2G) (Lamouille et al., 2014). 180 
As these features are typically associated with metastatic spread, we next employed a 181 
melanoma model to compare the lung colonization potential of diverse p53 truncating 182 
mutants. Specifically, we injected B16-F1 melanoma murine cells ectopically expressing 183 
the p53 W146*, R213*, G325* mutants, as well as the vector control Td-Tomato (Figure 184 
2- figure supplement 2), into C57BL/6J mice via tail vein as previously described 185 
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(Overwijk and Restifo, 2001). As shown in Figures 2H, 2I and Figure 2- figure 186 
supplement 4, at day 14 post-injection, we observed a dramatic increase in the number 187 
of melanoma colonies in lung in the case of cells expressing the p53 R213* mutant. 188 
 189 
TP53 exon-6 truncating mutations are expressed in and required for cancer cell 190 
survival 191 
 192 
In all eukaryotes, mRNA transcripts that contain premature stop codons might be 193 
detected and degraded by a surveillance pathway known as nonsense-mediated mRNA 194 
decay (NMD) (Bateman et al., 2003; Behm-Ansmant and Izaurralde, 2006). Yet, it has 195 
been shown that not all premature truncating transcripts undergo NMD, and that 196 
variation in NMD efficiency among different tissues, cell types and even individuals could 197 
lead to the expression of variable amounts of truncated proteins that could impact the 198 
clinical presentation and outcome of diseases. For example, no NMD-mediated mRNA 199 
diminution was observed in the lymphoblasts and bone cells of patients carrying 200 
premature termination codons in the collagen X gene (Bateman et al., 2003). 201 
 202 
As NMD could impair the potential activity of TP53 exon-6 truncating mutations, we 203 
compared the expression of TP53 exon-6 truncating mutations and p53-WT in multiple 204 
tumor samples and tumor-derived cell lines.  205 
Analysis of four individual sequencing studies done by the TCGA project indicated a 206 
large distribution in the expression of all p53 mRNAs and a comparable, though slightly 207 
decreased, expression of RNA transcripts harboring TP53 truncating mutations (Figure 208 
3A, Figure 3- figure supplement 1 and Supplementary File 2).  209 
 210 
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We confirmed that TP53 exon-6 truncating mutations partially escape NMD by western 211 
blot analysis of protein extracts from multiple tumor-derived cell lines harboring different 212 
TP53 mutations (Figure 3B). As shown in Figure 3C and in Figure 3- figure supplement 213 
3, we observed that p53 exon-6 truncating mutants were indeed expressed in the 214 
SW684, Calu-6 and DMS114 cell extracts. Notably, analyses of p53 expression upon 215 
knockdown with two independent p53 small hairpin RNAs (shRNA) verified that the 216 
bands we detected by western blot analysis corresponded to distinct p53 mutant forms 217 
(Figure 3C and Figure 3- figure supplement 3A). 218 
 219 
Our studies based on the ectopic expression of p53 exon-6 truncating mutants indicated 220 
a possible gain of function activity of these p53 truncated isoforms (Figure 2). Having 221 
previously shown that these mutants are expressed in cancer cells, we next extended 222 
our functional studies to include cancer cell lines harboring TP53 exon-6 truncating 223 
mutations.  224 
 225 
Acute inactivation of p53 (i.e., 2-4 days) with two independent p53 shRNAs in cells that 226 
exclusively expressed the p53 R213* and R196* mutants resulted in a down-regulation 227 
of EMT markers and up-regulation of E-cadherin (Figure 3D, and Figure 3- figure 228 
supplement 4A). This was consistent with the pro-metastatic activities we observed in 229 
cells ectopically expressing TP53 exon-6 truncating mutations and with the genetic data 230 
summarized in Figure 1 and Figure 2. 231 
 232 
Yet, prolonged inactivation (i.e., more than 6 days) of p53 in tumor-derived cell lines 233 
harboring TP53 exon-6 truncating mutations resulted in a dramatic decrease in the 234 
viability of the cells over time (Figures 3E and 3F). We confirmed that the decreased 235 
number of cells we found in our viability assay was due to an increase in cell death by 236 
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measuring levels of expression of the apoptotic marker cleaved-PARP upon p53 237 
knockdown (Figure 3- figure supplement 6). This appeared to be unique to cells 238 
expressing the R213* and R196* exon-6 truncating mutations (SW684, DMS114 and 239 
Calu-6) as silencing p53 in cell lines harboring (i) a wild type p53 allele (A549 and MCF7 240 
cells), (ii) a “hotspot” missense p53 mutant (AU565), (iii) a longer truncation (HCC1937), 241 
(iv) a shorter truncation (H2126), or (v) a p53 homozygous deletion (H1299) did not 242 
affect the number of viable cells (Figure 3F and 3G). 243 
 244 
To eliminate the possibility that these differences were due to the efficiency of p53 245 
inactivation or variance in the cells’ sturdiness, we next measured p53 knockdown 246 
efficiency as well as the effect of inactivation of the essential gene RPA3 on cell viability 247 
across all the cell lines (Figures 3F, 3G and Figure 3- figure supplement 5). In all cases 248 
we found similar efficiency of knockdown and comparable decrease in the viability of 249 
cells upon RPA3 silencing.  250 
 251 
To provide further validation to our findings we also employed an inducible CRISPR-252 
Cas9 system to inactivate p53 in in-vitro and in-vivo model systems (Senturk, Shirole et 253 
al., 2016) (Figures 3H, 3I and Figure 3- figure supplement 7). In these cases, the 254 
inactivation of p53 also resulted in a substantial decrease in cell viability only in those 255 
cells expressing TP53 exon-6 truncating mutations. 256 
 257 
p53 exon-6 truncated mutants partially localize to the mitochondria and regulate 258 
mitochondrial transition pore permeability by interaction with Cyclophilin D 259 
 260 
p53-psi is a naturally occurring alternative splice isoform generated by the use of an 261 
alternative cryptic splicing acceptor site in intron-6 (Figure 4- figure supplement 1) with 262 
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an approximate molecular weight of 35 kDa. As demonstrated in Senturk et al., a p53-psi 263 
like protein can also be generated by mutations occurring at the splice acceptor site in 264 
exon-7 (Hop62, c.673-2A>G TP53 mutation).  265 
 266 
From a molecular and phenotypic standpoint, the products of TP53 exon-6 truncating 267 
mutations highly resemble p53-psi (Figure 4- figure supplement 1). Like p53-psi, these 268 
p53 mutants lack most of the domains required for p53 canonical tumor suppressor 269 
activities (i.e., nuclear localization, oligomerization domains, and the alpha helix required 270 
for p53-DNA binding) and are capable of reprogramming the cells towards the 271 
acquisition of pro-metastatic features. Therefore, unsurprisingly, we not only found that 272 
p53 exon-6 truncating mutants were excluded from the nucleus (Figure 4B), but also that 273 
they lacked transcriptional activities (Figure 4C).  274 
 275 
Previous studies have indicated that p53-WT under stress conditions could localize to 276 
the mitochondria and bind to the mitochondria permeability transition pore (MPTP) 277 
regulator Cyclophilin D (CypD) through a domain present from amino acid 80 to amino 278 
acid 220 of the p53 protein (Vaseva et al., 2012). More recently Senturk et al., showed 279 
that p53-psi is constitutively localized to the mitochondria where it also binds to CypD. 280 
Specifically, they were able to demonstrate that the tumor promoting activities of p53-psi 281 
requires its molecular and functional interaction with CypD (Senturk, Yao et al. 2014) 282 
(Figure 4A).  283 
 284 
CypD is a peptidyl-prolyl isomerase and the only validated regulatory component of the 285 
MPTP (Baines et al., 2005; Schinzel et al., 2005; Giorgio et al., 2010). CypD activity can 286 
be pharmacologically inactivated by Cyclosporin A (CsA). CsA was initially isolated from 287 
the fungus Tolypocladium inflatum (Heusler and Pletscher, 2001). It is best known as an 288 
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immunosuppressant drug that reduces the activity of the immune system by interfering 289 
with the activity and growth of T cells (Bunjes et al., 1981). In addition to its effect on T 290 
cells, CsA has also been shown to be a potent inhibitor of CypD by preventing the 291 
binding of CypD to other components of the MPTP (Halestrap and Davidson, 1990, 292 
Nicolli et al., 1996; Baines et al., 2005).  293 
 294 
As the domains that are required for p53 mitochondria localization and its interaction 295 
with CypD are conserved in TP53 exon-6 truncating mutations, we examined the sub-296 
cellular distributions of different p53 truncating mutants and their interactions with CypD. 297 
We found that p53 exon-6 truncating mutants were partially localized to the mitochondria 298 
(Figure 4D and Figure 4- figure supplement 2) and, as shown by our 299 
immunoprecipitation experiments, could bind to CypD in the mitochondrial fractions 300 
(Figure 4E). The binding of p53 exon-6 truncating mutants with CypD was not due to 301 
changes in the expression of CypD, as neither the ectopic expression of TP53 exon-6 302 
truncating mutations nor decreasing their expression had any effects on CypD 303 
expression or its mitochondrial localization (Figure 4- figure supplement 2 and 6). 304 
Similarly, knockdown of CypD in cells expressing p53-psi or exon-6 truncating mutants 305 
did not affect the localization of truncated p53 isoforms to mitochondria (Figure 4- figure 306 
supplement 7). 307 
 308 
To test the functional role of a CypD/p53 exon-6 truncations interactions, we analyzed 309 
changes in the permeability of the MPTP by using a calcein fluorescence assay in cells 310 
ectopically expressing W146*, R196*, R213*, p53-psi and G325*. We found an 311 
increased permeability of the MPTP only in the case of p53-psi and the R196* and 312 
R213* mutants. Interestingly, in the cells expressing the W146* p53 mutants we instead 313 
observed a decrease of MPTP permeability (Figure 4F).  314 
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 315 
To confirm that these changes in mitochondrial permeability were dependent on CypD, 316 
we then inhibited CypD activity using CsA. We found that in the presence of CsA, the 317 
increase in the pore permeability that we observed in cells expressing R196*, R213* p53 318 
exon-6 mutants and p53-psi was completely ablated (Figure 4F). To further validate the 319 
possible function of p53 exon-6 truncations and p53-psi in regulating the MPTP function, 320 
we performed similar experiments in tumor-derived cell lines with p53-psi splicing 321 
mutation (Hop62), exon-6 truncating mutation (SW684, DMS114 and Calu-6), p53-WT 322 
(A549, MCF7), a shorter truncation (H2126) and a p53 homozygous deletion (H1299) 323 
upon knock down of p53. As shown in Figure 4G, only cells expressing p53-psi and 324 
exon-6 truncating mutations showed a decrease in mitochondrial permeability after the 325 
knockdown of p53. Similarly, CypD silencing resulted in a decrease in mitochondrial 326 
permeability only in those cells expressing p53-psi and exon-6 truncating mutations 327 
(Figure 4- figure supplement 4A and 4C).  328 
 329 
An increase in the mitochondria pore permeability is predicted to reduce the 330 
mitochondrial polarization. Hence, we also performed a JC-1 based assay to analyze 331 
any changes in the mitochondrial polarization upon inactivation of p53 and CypD. As 332 
shown in Figure 4H and Figure 4- figure supplement 4B, knockdown of p53 or CypD in 333 
cell lines expressing p53-psi and exon-6 truncating mutations specifically resulted in the 334 
hyperpolarization of mitochondria.  335 
 336 
Cyclophilin D activity is required for phenotypes associated with TP53 exon-6 337 
truncating mutations 338 
 339 
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Having shown that p53 exon-6 truncating mutants and p53-psi regulate the MPTP in a 340 
CypD dependent fashion (Figure 4), we next conducted studies aimed at understanding 341 
a functional role of the inner pore regulator CypD in mediating the acquisition of pro-342 
metastatic features and survival in cells expressing p53-psi or p53 exon-6 truncating 343 
mutants. To this end, we genetically reduced the expression of CypD either by shRNA 344 
mediated knockdown in-vitro or by CRISPR-Cas9 mediated gene editing in a mouse 345 
model system.  346 
 347 
Figure 5A demonstrates that short-term inactivation of CypD led to a decrease in 348 
mesenchymal markers in cells specifically expressing p53-psi or exon-6 truncating 349 
mutants (Hop62, DMS114 and Calu-6).  When p53 was inactivated in these cells, we 350 
observed a reduction in cell viability; analogously, CypD long-term knockdown also led 351 
to a reduction in viable cells in in-vitro cell viability experiments (Figures 5C, 5D and 352 
Figure 5- figure supplement 1B). This result was also recapitulated by treatment of cells 353 
with the novel CypD inhibitor, C-9 (Figure 5B) (Valasani et al; 2016).  354 
To provide evidence that the dependency of cells expressing p53 exon-6 truncating 355 
mutants on CypD expression was not only restricted to in-vitro settings, we next 356 
extended our studies to an in-vivo model system based on sub-cutaneous 357 
transplantation of tumor cell lines in immune-compromised mice. Figures 5E and 5F 358 
show that the inactivation of CypD expression in xenograft models using an inducible 359 
CRISPR-Cas9 gene editing system decreased the tumor volume of p53 exon-6 360 
truncating mutant-expressing cells (Calu6), but not the tumor volume of p53-WT 361 
expressing cells (A549) (Figure 5- figure supplement 2).  362 
 363 
DISCUSSION 364 
 365 
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In summary, our analysis of human tumors, combined with the detailed molecular 366 
characterization of TP53 exon-6 truncating mutations, offers strong support for the idea 367 
that chromosome 17p deletions and, particularly, TP53 mutations produce a multiplicity 368 
of alleles with diverse activities that contribute differently to tumorigenesis by providing 369 
distinct, selective advantages (Petitjean et al., 2007; Brosh and Rotter, 2009; Olivier et 370 
al., 2010; Oren and Rotter, 2010; Liu et al., 2016). Our studies, in fact, revealed that p53 371 
exon-6 truncating mutants not only lack transcriptional activities and the capacity to 372 
respond to DNA damage, but are also uniquely able to activate a pro-tumorigenic 373 
cellular program. 374 
 375 
Consistent with the capabilities of these p53 mutants to promote rather than halt 376 
tumorigenesis, TP53 exon-6 truncating mutations are highly abundant and are enriched 377 
in certain tumors (Figure 1). Although, in principle this implies that these specific mutants 378 
could increase the fitness of tumors, we cannot exclude the possibility that the higher 379 
than expected frequency we observed in tumors could alternatively be explained by a 380 
specific etiology and/or a particular mutagenic modality. Additional experiments in 381 
mouse model systems will be required to better understand the ontogeny of these 382 
mutations.  383 
 384 
One interesting feature of the p53 exon-6 truncating mutants is their similarity to the 385 
naturally occurring p53 isoform p53-psi. Much like p53-psi, they lack part of the DNA 386 
binding and oligomerization domains as well as the nuclear localization sequences; 387 
however, they are partially localized to the mitochondria where they are able to bind and 388 
activate Cyclophilin D.  389 
 390 
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 CypD is a positive regulator of the opening of the MPTP. Inhibition of CypD activity, 391 
either genetically or pharmacologically, has been reported to reduce mitochondrial 392 
permeability and induce changes in mitochondrial membrane potential. Hence, 393 
unsurprisingly, we observed that the expression of TP53 exon-6 truncating mutations is 394 
sufficient to increase the MPTP.  395 
 396 
In the past, an augmented mitochondrial permeability has always been associated with 397 
decreased cell viability. Yet, cells expressing TP53 exon-6 truncating mutations are 398 
proliferating under normal conditions and are actually dependent on CypD for their 399 
survival.  These observations are consistent with more recent reports indicating that the 400 
MPTP has a role not only in inducing cell death under cellular stress, but also in 401 
physiological processes (Kwong and Molkentin et al., 2015) and in the induction of 402 
phenotypic changes associated with pro-metastatic features (Senturk, Yao et al., 2014).  403 
The requirement of mitochondria localization, interaction with CypD and the lack of 404 
transcriptional activities distinguish TP53 exon-6 truncating mutations from other p53 405 
gain of function mutants with pro-tumorigenic functions (e.g. R175, G245, R248, R249, 406 
R273 and R282). Despite the fact that p53 gain of function mutants are also capable of 407 
inducing pro-metastatic features, we found that their activities strongly depend on their 408 
nuclear localization and transcriptional activities. 409 
 410 
In our study, structure-function analysis has also shown that the p53 W146* mutant is 411 
unable to interact with CypD despite its ability to localize to the mitochondria. 412 
Interestingly and contrary to p53-psi and p53 exon-6 truncating mutants, the expression 413 
of the p53 W146* mutant increased the expression of E-cadherin instead of reducing it 414 
(Figures 2D and 2E), and decreased the permeability of the MPTP in a calcein assay 415 
(Figure 4F). To explain this observation, it is tempting to speculate that the p53 W146* 416 
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mutant may interact with other components of the MPTP and antagonize the function of 417 
CypD. Further studies will be required to illuminate the underpinning mechanisms. 418 
 419 
The selective dependencies of cancer cells harboring exon-6 TP53 truncating mutations 420 
to CypD activity (Figure 5B-F) is particularly exciting, as it begs the design of novel 421 
targeted therapeutics. Notably, the high prevalence of p53-psi or TP53 exon-6 truncating 422 
mutations in certain tumors also suggests that this class of TP53 mutations represents a 423 
strong precision medicine candidate target comparable to the well-documented EGFR, 424 
ROS and ALK mutations in NSCLC (Korpanty et al., 2015). 425 
 426 
In conclusion, our studies indicated that multiple TP53 exon-6 truncating mutations, 427 
despite lacking transcriptional and canonical p53 tumor suppressor activities, can 428 
reprogram the cells’ signaling networks, change the “dependency” of cells and their cell 429 
state. As these mutations structurally and functionally mimic the naturally occurring p53-430 
psi isoform, we propose that TP53 exon-6 mutations are best described as “separation 431 
of function” rather than simply “gain of function” or “loss of function.” Interestingly, 432 
approximately one-third of all human genetic disorders are caused by mutations that 433 
generate premature stop codons (Frischmeyer et al., 1999). Hence, TP53 exon-6 434 
truncating mutations could represent a paradigm for other diseases that could similarly 435 
be driven by separation of function isoforms. 436 
 437 
 438 
  439 
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MATERIAL AND METHODS 440 
 441 
Animals 442 
Xenograft assay:  443 
All animal experiments were performed in accordance with National Research Council’s 444 
Guide for the Care and Use of Laboratory Animals. Protocols were approved by the Cold 445 
Spring Harbor Laboratory Animal Care and Use Committee. Female NU/NU mice 6-446 
weeks old were purchased from Charles River. A549 and Calu-6 lung cancer cells were 447 
plated and infected in-vitro with lentiviruses carrying Renila and p53 sgRNAs at a 448 
multiplicity of infection (MOI) of 1. Xenograft tumors of A549 and Calu-6 cells with 449 
inducible-cas9 expression were established by subcutaneous injection of 5x105 cells in 450 
100 µL volume mixed with 1:1 dilution basement membrane matrix with biological activity 451 
(Matrigel, BD Biosciences). Three to four animals per group were used in each 452 
experiment. When tumors reached a palpable size, animals were administered with 1 µg 453 
peritumoral injection of Shield-1 (diluted in 100 µL PBS), once per day for the duration of 454 
four days. Tumor growth was followed for two weeks using a vernier caliper (volume = 455 
((dshort)2 × (dlong))/2). At the end of the experiment, the mice were sacrificed. Tumors 456 
were extracted and fixed in freshly prepared 4% paraformaldehyde for 24h.  457 
Tail vein assay: 458 
Tail vein assay for B16-F1 cells with p53 truncations was conducted as previously 459 
described (Overwijk and Restifo, 2001). B16-F1 cells were collected at 50% confluency 460 
and a final suspension of cells with 4x105 cells/mL was prepared in HBSS buffer. 461 
C57BL6 mice were injected with 0.5 mL of cell suspension intravenously in the tail vein. 462 
Since B16-F1 melanoma have inherent colonization property, the mice were sacrificed at 463 
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day 14 post-injection. We changed the end-point of experiment to day 14 instead of 18 464 
to avoid saturation of lung with melanoma colonies which would had underestimated the 465 
increase in colonization potential of specific clone. For quantification of lung colonies, 466 
extracted lungs were fixed in freshly prepared 4% paraformaldehyde for 24h. After 467 
fixation, lungs were embedded in agarose, sectioned vertically and transferred to slides 468 
for H&E staining. 469 
Cell Lines 470 
All cell lines were obtained from American Type Culture Collection (ATCC), except 471 
Hop62 which was obtained from National Cancer Institute (NCI) with provided 472 
information of authenticity in the year 2015. All of the cell lines were regularly monitored 473 
for mycoplasma contamination by using Lonza mycoalert mycoplasma detection kit as 474 
per the manufacturer’s instructions. All the cell lines tested negative for Mycoplasma 475 
contamination. A549 (RRID: CVCL_0023), AU565 (RRID: CVCL_1074), H1299 (RRID: 476 
CVCL_0060), HCC1937 (RRID: CVCL_0290) and Hop62 (RRID: CVCL_1285) cells 477 
were cultured in RPMI supplemented with 10% Fetal Bovine Serum (FBS, HyClone), 478 
Penicillin-Streptomycin (10,000 units/mL, Gibco). B16-F1 (RRID: CVCL_0158), Calu-6 479 
(RRID: CVCL_0236), H2126 (RRID: CVCL_1532), HEK-293T (RRID: CVCL_0063), 480 
MCF7 (RRID: CVCL_0031), and SW684 (RRID: CVCL_1726) cells were cultured in 481 
DMEM supplemented with 10% Fetal Bovine Serum (FBS, HyClone), Penicillin-482 
Streptomycin (10,000 units/mL, Gibco). DMS114 (RRID: CVCL_1174) cells were 483 
cultured in Waymouth media supplemented with 10% Fetal Bovine Serum (FBS, 484 
HyClone), Penicillin-Streptomycin (10,000 units/mL, Gibco). All of the cell lines were 485 
incubated at 37°C with 5% CO2 incubation.  486 
Generation of Cell lines 487 
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For the constitutive ectopic expression of p53-WT, p53-psi and other p53 truncated 488 
forms, we used a lentiviral gene expression system. cDNAs encoding p53-WT, p53-psi 489 
and different p53 truncations were cloned into the pENTR4 (Invitrogen) vector by using 490 
A549 cells cDNA as a template for TP53. Using the Gateway technology, each pENTR4 491 
vector was recombined with pENTR5 vector and pLenti6.4 destination vector. For our 492 
experiment, we used pENTR5 vector that contains the human EF-1α promoter. 493 
Virus production 494 
a) For pLenti6.4 System: HEK-293T cells were co-transfected with the constructs 495 
encoding the genes of interest with the packaging plasmids as LP1, LP2 and p-VSV-G 496 
using lipofectamine 2000 reagent (Life Technologies). 10 mL of virus particles were 497 
collected after 48h of transfection by clarifying the supernatant through 0.45 µm filter 498 
membrane. Cells were infected and selected by blasticidin at concentration of 10 ug/mL 499 
in 3-5 days. 500 
b) For PLKO.1 shRNA System: All shRNA constructs were obtained from Sigma-Aldrich, 501 
except PLKO.1 scrambled and p53-773 that were obtained from Addgene. HEK-293T 502 
cells were co-transfected with the PLKO.1 constructs with the packaging plasmids as 503 
BH10, Rev and VSV-G using lipofectamine 2000 reagent. 10 mL of virus particles were 504 
collected after 48h of transfection by clarifying the supernatant through 0.45 µm filter 505 
membrane. The sequence of shRNAs used in this study is listed in Supplementary File 506 
4. 507 
c) For DD-Cas9 System: DD-Cas9 (Destabilized Cas9) system was designed in lab by 508 
(Senturk, Shirole et al., 2016). sgRNAs were designed using an algorithm on 509 
http://crispr.mit.edu/. Virus packaging was achieved by transiently co-transfecting HEK-510 
293T cells on 10 cm culture dish with the constructs encoding the sgRNAs of interest 511 
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with DD-Cas9 along with the packaging plasmid psPAX2 and envelope plasmid pMD2.G 512 
(Didier Trono, Addgene) using lipofectamine 2000 reagent. 10 mL of viral particles were 513 
collected after 48h of transfection by clarifying the supernatant through 0.45µm filter 514 
membrane. Virus transduction was optimized in order to achieve low MOI transduction. 515 
Typically, 500-2000 µL virus particles from 10 mL stock were used to infect 1x106 cells 516 
on a 10 cm culture dish in 10 mL total volume of culture medium. Shield-1, obtained from 517 
Cheminpharma, was solubilized in pure ethanol and was added to culture media with 518 
given concentrations. The sequence of oligonucleotides for cloning all sgRNAs used in 519 
this study is listed in Supplementary File 5. 520 
Western Blot Analysis  521 
Protein samples were isolated by re-suspending cell pellets in RIPA buffer (50 mM Tris-522 
HCl at pH 7.6, 150 mM NaCl, 1% NP-40, 0.5% Na deoxycholate, 0.1% SDS with 523 
Protease inhibitors). After removal of the debris, samples were quantified with 524 
colorimetric BCA kit (Pierce). For p53 expression 10 µg of protein extract for p53-WT 525 
expressing cells and ectopic expression cell lines or 50-75 µg of protein extract for p53 526 
truncation expressing cells lines were electrophoresed on 6-12% gradient gels and wet-527 
transferred to nitrocellulose membranes. For other proteins 20 µg of protein extract were 528 
electrophoresed on 6-12% gradient gels and wet-transferred to nitrocellulose 529 
membranes. After 1h blocking with 5% nonfat dry milk in 1X TBS, 0.1% Tween20 at 530 
room temperature, membranes were incubated with antibodies diluted in 1% w/v BSA as 531 
follows; p53-DO1 mouse mAb(1:1000, EMD Millipore, RRID: AB_213402), α-tubulin 532 
DM1A mouse mAb (1:50000, EMD Millipore, RRID: AB_11204167), Anti-Ras-GAP  533 
mouse mAb (1:1000, BD Biosciences, RRID: AB_397455), Tom 20 (FL145) rabbit 534 
polyclonal Ab (1:1000, Santa-Cruz, AB_2207533), PARP (46D11) Rabbit mAb (1:1000, 535 
Cell signaling technology, RRID: AB_10695538) cleaved PARP (Asp214) Rabbit  Ab 536 
 23
(1:1000, Cell signaling technology, RRID: AB_331426), p42/44 MAPK (ERK1/2) 537 
antibody (1:1000, Cell signaling technology, RRID: AB_330744)  and CypD mouse mAB 538 
(1:5000, Abcam, RRID: AB_10864110). All incubations were performed overnight at 40C. 539 
Membranes were rinsed thoroughly with 1X TBS-T and then incubated with species-540 
specific HRP-tagged secondary antibodies (1:10000, Bio-Rad). Western blots were 541 
developed by incubating the membranes with Supersignal west femto maximum 542 
sensitivity substrate diluted in Pierce ECL western blotting substrate (1:10 v/v) solution 543 
(Thermo Scientific) for 4 min. 544 
RNA Isolation and RT-qPCR  545 
Cells were rinsed twice and harvested with ice cold PBS. Pellets were lysed in 800 μL 546 
Trizol (Invitrogen) and RNA was extracted according to the manufacturer’s instructions. 547 
Contaminating DNA was removed by RNase-free DNase (Promega) treatment for 30 548 
min at 370C. cDNA was prepared from 2 μg total RNA using ImProm-II Reverse 549 
Transcription System (Promega) with 16mer oligo(dT). RT-qPCR was performed using 550 
Power SYBR Green PCR Master Mix as per the manufacturer’s instruction (Applied 551 
Biosystems).  552 
 553 
 554 
Cell growth assay 555 
For cell growth assay, an equal number (5000-15000 cells/well) of cells was plated in 556 
quadruplets in 12-well plates (BD falcon) after infection with either shRNAs or DD-Cas9 557 
virus particles. Cell growth was followed for 8-15 days, and media was changed every 3-558 
4 days. The cells were split at intermitted time points to avoid reaching over-confluency. 559 
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Cells were washed with PBS to get rid of the floating cells and fixed in 4% Formaldehyde 560 
in PBS (V/V) for 10-15 min. Fixed cells were stained by staining solution (0.1% Crystal 561 
violet in 10% ethanol) for 20 min. The staining solution was aspirated from the wells, and 562 
the cells were washed with water three times to get rid of any extra stain. Stained cells 563 
were air dried and imaged by using Licor Odyssey. To quantify the cell numbers, cells 564 
were destained by using 10% Acetic acid and absorbance of de-stained solution was 565 
measured at 590 nm at appropriate dilutions. 566 
Wound Healing Assay 567 
To perform the wound-healing assay, cells were plated in a 6-well plate (BD-Falcon) and 568 
allowed to grow up to 80-90% confluency. A wound was introduced using a P200 tip, 569 
and was imaged at indicated time points using a Zeiss Observer Live Cell inverted 570 
fluorescence microscope. The quantification of wound closure was performed by 571 
measuring3 the length of wound at indicated times by using ImageJ software.  572 
Invasion Assay 573 
Cell invasion assay was performed using a Cytoselect 24-well cell invasion assay 574 
Basement membrane kit as per manufacturer’s instructions (Cell Biolabs Inc). 575 
 576 
Immunofluorescence 577 
Cells were grown on glass coverslips in 24-well cell culture plates and collected at 578 
appropriate confluency. Cells were fixed with 4% Para-formaldehyde and permeabilized 579 
in 0.1% Triton X-100 in PBS for 10 min. Fixed cells were washed three times in PBS and 580 
blocked with 1% BSA in PBS for 1h. After washing three times with PBS, cells were 581 
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incubated with the primary antibody diluted in 1% BSA for overnight at 40C. Immune 582 
complexes were then stained with the indicated secondary antibodies (Invitrogen). DAPI 583 
was used for nuclear staining. Stained cells were mounted with Vectashield mounting 584 
medium (Vector Laboratories) and analyzed under confocal microscope. The Antibodies 585 
used for immunofluorescence were p53-DO1 mouse mAb (1:100, EMD Millipore) and E-586 
Cadherin (1:200, BD Biosciences). Alexa Fluor 488-tagged phalloidin (Thermo Fisher 587 
Scientific) was used to stain actin stress fibers as per the manufacturer’s 588 
recommendation. 589 
Immunohistochemistry 590 
Tissues were fixed in 10% neutral buffered formalin for 24h and then transferred to PBS. 591 
Tissues were embedded in paraffin and 5-μm sections were processed for hematoxylin–592 
eosin staining and immunohistochemistry. Antigen was retrieved by using citrate buffer 593 
at pH 6.0 at high heat and pressure for 30 min. Endogenous peroxidases were blocked 594 
with 3% hydrogen peroxide (10 min), followed by serum blocking (1h). Primary 595 
antibodies were incubated overnight at 4 °C. Secondary antibodies (ImmPRESS 596 
Reagent Anti-Mouse IgG and Anti-Rabbit IgG from Vector Labs) were incubated at room 597 
temperature for 1h. Antigens were developed with ImmPACT DAB kit (Vector Labs) 598 
peroxidase substrate. Primary antibodies used were Mouse anti-p53 antibody (OP43, 599 
Calbiochem Miilipore, 1:1,00); Rabbit anti-CypD antibody (ab155979, abcam, 1:50). 600 
Mitochondrial Fractionations 601 
After cultured cells were trypsinized, counted, and washed with PBS, mitochondria were 602 
extracted from 107 cells using a Mitochondria isolation kit (MACS Miltenyi Biotech) 603 
containing anti-Tom22 mitochondria specific magnetic microbeads. After extraction, the 604 
mitochondria were lysed in buffer A (150 mM NaCl, 5 mM EDTA, 1% digitonin, and 50 605 
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mM Tris-HCl pH 7.5) for 1h. The amount of protein collected was quantified using a BCA 606 
kit, and samples were electrophoresed as described earlier. The purity of fractions was 607 
determined by immunoblotting with different cellular compartment markers. 608 
Immunoprecipitation 609 
For immunoprecipitation mitochondrial fractions were lysed as described earlier. Lysed 610 
fractions were pre-cleared with agarose IgG beads for 30 min. FLAG tagged p53 was 611 
immunoprecipitated from 550 ug of mitochondrial lysate with monoclonal Anti-FLAG M2 612 
mouse antibody (Sigma-Aldrich, RRID: AB_262044) at 4°C overnight on rotator. 613 
Samples were next washed 5 times with buffer B (150 mM NaCl, 5 mM EDTA, 0.5% 614 
digitonin, 1% triton X-100 and 50 mM Tris-HCl pH 7.5). The immunoprecipitated proteins 615 
were eluted and analyzed by immunoblotting for CypD binding. 616 
Mitochondrial Permeability Transition Pore (MPTP) Assay 617 
To measure change in the mitochondrial permeability transition pore (MPTP) opening, 618 
p53 truncation-expressing cell lines were infected with p53 or CypD shRNA. Cells were 619 
collected post infection at 96h. Alterations in the functionality of MPTP were measured 620 
by assessing changes in calcein fluorescence by using MPTP kit (Biovision K239-100) 621 
as per the manufacturer’s instructions. To measure MPTP opening, ectopically 622 
expressing p53 truncations cells were grown in 2% FBS for 36h and were treated with 623 
vehicle or 2 μM of CsA for 2h before collecting for analysis. To analyze the degree of 624 
pore opening quenching of calcein fluorescence by CoCl2 is measured. As shown below, 625 
higher the calcein fluorescence in presence of CoCl2, more the decrease in pore 626 
permeability, and vice-versa. 627 
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 628 
JC-1 Assay 629 
To measure the change in mitochondrial polarization, p53 truncations expressing cell 630 
lines were either infected with p53 or CypD shRNA. Cells were collected post-infection at 631 
96h, and mitochondrial polarization was measured using the MitoProbe JC-1 assay kit 632 
manufacturer’s instructions (Thermo Fisher Scientific-M34152). 633 
 634 
Drug Sensitivity Assay 635 
For the drug sensitivity assay, an equal number (2000-8000 cells/well) of cells was 636 
plated in quadruplets in 24-well plates (BD falcon). After 24h, different concentrations of 637 
C-9 were added to the cells. At indicated time points, cells were washed with PBS, fixed 638 
with formaldehyde, stained with crystal violet and quantified as described earlier. 639 
Data Analysis 640 
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All mutation data was obtained from the MSKCC cBioPortal (http://www.cbioportal.org). 641 
Statistical analyses were performed in R (http://cran.r-project.org/) (RRID:SCR_003005). 642 
Fisher’s exact test was used to compare observed versus expected occurrence of 643 
various types of TP53 mutation. Both nonsense mutations occurring in exon-6 and 644 
frameshift mutations wherein a premature stop codon was introduced in exon-6 were 645 
considered as exon-6 truncations. 646 
All data and statistical analyses were performed using GraphPad Prism Software (RRID: 647 
SCR_002798). 648 
  649 
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FIGURE LEGENDS. 844 
 845 
Figure 1: TP53 exon-6 truncating mutations occur at higher than expected 846 
frequency. A. Distribution of TP53 nonsense (top, black) and missense (bottom, green) 847 
mutations in the TCGA cohort (n=2,521 tumors). Domains are demarcated on the upper 848 
baseline as follows: trans-activating domains (orange), Proline rich domain (green), DNA 849 
binding domain (light blue), nuclear localization sequence (yellow), and oligomerization 850 
domain (purple). The lower baseline and Roman numerals below indicate TP53 exon 851 
location relative to the p53 coding sequence. B. Analysis as in A in the MSKCC cohort 852 
(n=3,797 tumors). C-D. Recurrence frequency of each mutation type per unique change 853 
per sample in the TCGA and MSKCC cohorts respectively (Missense, p<2.2e-16; other 854 
nonsense, p=0.00178 and exon-6 nonsense, p=3.869e-11, Fisher’s exact test). E. Count 855 
of unique reported amino acid changes and observed instances of exon-6 nonsense, 856 
other nonsense, missense, or all mutations. F. Frequency of TP53 alteration vs. 857 
frequency of TP53 truncating mutations by cancer type. Circles were plotted in 858 
proportion to the frequency of TP53 exon-6 truncation mutations. See Supplementary 859 
File 1 for cancer type abbreviations. G. The pie charts represent the relative frequency of 860 
TP53 mutation type for colorectal cancer primary tumors (top left, n=403) and 861 
metastases (top right, n=395). Mutations are indicated as follows: splice site mutations 862 
(Splice, light blue, p=0.035, fisher’s exact test), exon-6 nonsense mutation (Ex6 NS, 863 
orange, p=0.041), other nonsense mutation (Other NS, pink), in-frame insertion/deletion 864 
(IF indel, yellow), frameshift insertion/deletion (FS indel, gold), missense mutation (MS, 865 
green), multiple mutations (Multiple, purple), or no TP53 mutation (None, white). Note 866 
that both exon-6 nonsense mutations (p-value = 0.041) and missense mutations (p-867 
value = 0.035) are over-represented in the metastatic samples with respect to p53-WT 868 
cases, whereas nonsense mutations outside of exon-6 and missense mutations are not 869 
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(Fisher's exact test). The lower chart indicates the ratio of frequency in metastases to 870 
primary colorectal cancers of the indicated TP53 mutations. See Supplementary File 3 871 
for number of tumor samples with TP53 mutation in primary CRC and metastatic CRC. 872 
 873 
Figure 2: p53 exon-6 truncating mutants reprogram cells towards the acquisition 874 
of pro-metastatic features. A. Schematic of p53 and position of p53 nonsense 875 
mutations utilized in this study. Domains are demarcated and TP53 exon locations 876 
relative to the p53 coding sequence are indicated in the Roman numerals. B. Different 877 
p53 truncations were ectopically expressed in the p53 null H1299 and p53-WT A549 cell 878 
lines. Expression was verified by western blot analysis of cell extracts by p53 N-terminal 879 
specific (DO1) antibody and the RasGAP as loading control after 48h post infection. C. 880 
p53 C-terminal truncations lack tumor suppressor capabilities. The chart indicates the 881 
number of viable cells relative to Td-Tom expressing cells at 72h post infection. Each bar 882 
is the mean of 9 replicates (p-value *<0.0005 unpaired t-test). D. Immuno-staining of 883 
A549 cells with phalloidin (green), E-cadherin (red) and DAPI (blue). Note that cells 884 
expressing R196* and R213* are characterized by different morphology, presence of 885 
stress fibers and decreased expression and localization of E-cadherin. E. RT-qPCR 886 
analysis of EMT markers in A549 cells expressing different p53 truncations. mRNA 887 
expression was quantified by SYBR-green-based RT-qPCR. Each bar is the average of 888 
3 replicates and represents mRNA expression of the indicated genes relative to GAPDH 889 
(p-value *<0.05 and **<0.005, unpaired t-test). F. p53 exon-6 truncating mutants 890 
augment the cell motility in A549 cells. Quantification of a scratch wound-healing assay 891 
is presented. Values in the chart represent mean ± SD of length of wounds at the 892 
indicated time points. For statistical analysis, the wound length at each time point for a 893 
given truncation was compared to Td-Tom expressing cells (n=12, p-value *<0.0005, 894 
**<0.00005 and ***<0.000005, unpaired t-test). See Figure 2- figure supplement 1A for 895 
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representative images of wounds closure. G. The chart represents the quantification of a 896 
trans-well matrigel cell invasion assay. Each bar is the mean ± SD from 6 independent 897 
experiments (p-value *<0.005, unpaired t-test). H. C57BL/6J mice were intravenously 898 
injected (tail vein) with B16-F1 melanoma cells ectopically expressing the indicated 899 
constructs. After 14 days, the lungs were dissected and the number of melanoma 900 
colonies in lung were quantified. The upper and lower panels illustrate representative 901 
dorsal (D) and ventral (V) images of the lungs. See Figure 2- figure supplement 2 for 902 
expression of truncations and Figure 2- figure supplement 4 for the histological analysis. 903 
I. The chart represents the number of melanoma colonies in lung in different p53-904 
truncation expressing cells. Each bar is the average number of melanoma colonies in 905 
the lungs of individual mice with data pooled from three independent experiments (Mean 906 
± SD, p-value *<0.005).  907 
 908 
Figure 3: TP53 exon-6 truncating mutations are required for EMT and cell survival. 909 
A. The chart represents the median distribution of mRNA transcripts from the indicated 910 
tumors with p53 truncating mutation (Red) and no mutation (Blue), based on TCGA 911 
datasets. See Figure 3- figure supplement 1 and Supplementary File 2 for further details. 912 
B. The table summarizes TP53 mutations status in the cell lines utilized in this study. C. 913 
Western blot analysis of the indicated cell lines using a p53 N-terminal specific (DO1) 914 
antibody and an antibody against RasGAP as loading control. Quantification is provided 915 
in Figure 3- figure supplement 3B. D. The chart represents mRNA expression analysis of 916 
the indicated genes in A549, SW684 and Calu-6 cell lines. mRNA expression was 917 
quantified by SYBR-green-based RT-qPCR. Each bar is the average of 3 replicates and 918 
represents mRNA expression of the indicated gene relative to GAPDH (p-value *<0.05 919 
and **<0.005, unpaired t-test). Analysis of additional cell lines is provided in Figure 3- 920 
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figure supplement 4A. E. Each dot represents the percentage of viable cells compared to 921 
scramble shRNA in cells expressing p53-WT (A549) or exon-6 truncating mutations 922 
(SW684 and DMS114) upon knockdown of p53 with two independent shRNA constructs. 923 
Each dot represents the mean of 9 individual replicates. Efficiency of knock down is 924 
provided in Figure 3- figure supplement 4B. F. Crystal violet staining of the indicated cell 925 
lines upon p53 knockdown with two independent p53 shRNAs. A scramble shRNA was 926 
used as a negative control while shRNA targeting the essential gene RPA3 was used as 927 
a positive control. The quantification of knockdown efficiency is provided in Figure 3- 928 
figure supplement 5. G. The chart depicts the percentage of viable cells 8 days post 929 
infection with the indicated shRNA constructs relative to scramble shRNA control. Each 930 
bar represents the mean of 9 individual replicates (p-value *<0.005, **<0.0005, unpaired 931 
t-test). See Figure 3- figure supplement 5 for knockdown efficiency. See Supplementary 932 
File 4 for shRNA sequences. H. Workflow of the transplantable model system used in 933 
this study. A549 (p53-WT) and Calu-6 (p53 R196*) cells were transduced with lentivirus 934 
constructs expressing an inducible CRISPR-Cas9 (DD-Cas9) targeting p53 (p53 g.140) 935 
and as negative control targeting Renila (Ren.g.208). Cells were transplanted sub-936 
cutaneously in immune-deficient mice. When the tumors reached an approximate size of 937 
4-5 mm in diameter; mice were treated with Shield-1 (1 µg). Tumor volume was 938 
determined at the indicated time points. See Supplementary File 5 for sgRNA 939 
sequences. I. The charts illustrate quantification of tumor volumes (mean ± SD) in the 940 
indicated cohorts at given time points (n=4, p-value *<0.05, unpaired t-test). Validation of 941 
p53 inactivation is provided in Figure 3- figure supplement 7B and 7C. 942 
Figure 4: CypD activity is required for phenotypes associated with TP53 exon-6 943 
truncating mutations. A. Schematic of p53-psi activities as reported by Senturk et al., 944 
unlike from p53-WT, p53-psi does not localize in the nucleus and does not have 945 
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transcriptional capabilities. Yet, p53-psi can translocate to the mitochondria where it 946 
binds to CypD and via modification of the inner pore permeability induces pro-metastatic 947 
features. B. p53 truncating mutants are excluded form the nucleus. Immuno-staining of 948 
H1299 cells with the p53 N-terminal specific (DO1) antibody (red). DAPI (blue) is used 949 
as counterstain. C. The chart represents expression of p53 target genes upon ectopic 950 
expression of different p53 truncations in A549 cells either in the absence or presence of 951 
Doxorubicin (1uM) for 24h. mRNA expression was quantified by SYBR-green based RT-952 
qPCR. Each bar is the average of 3 replicates and represents mRNA expression of the 953 
indicated genes relative to GAPDH (p-value, *<0.05, **<0.005 and ***<0.0005 unpaired 954 
t-test). D. p53 truncating mutants are partially localized in the mitochondria. Western blot 955 
analysis of total cell extracts and of mitochondrial fractions shows translocation of p53 956 
truncations in mitochondria. Purity of fractions were verified with antibodies specific for 957 
the mitochondria matrix protein CypD, mitochondria outer-membrane associated protein 958 
Tom20, nuclear protein PARP and cytoplasmic protein p42/44. E. Immuno-precipitation 959 
analysis of mitochondrial fraction from H1299 cells expressing FLAG-tagged different 960 
p53 truncations. Cell extracts were immuno-precipitated with a FLAG specific antibody 961 
and analyzed by western blot with a p53 N-terminal specific (DO1) antibody and CypD 962 
specific antibody. F. p53 truncating mutants increase the mitochondria inner pore 963 
permeability. See Material and Methods for details on assay design. The graph indicates 964 
relative number of H1299 cells expressing different p53 truncations that retain calcein 965 
fluorescence in mitochondria, upon CoCl2 treatment, in presence or absence of CsA 966 
(2uM) (n=3, p-value *<0.05, unpaired t-test). 967 
 G. The graph indicates the percentage of cells retaining calcein fluorescence in 968 
mitochondria upon CoCl2 treatment in the indicated cell lines upon p53 knockdown with 969 
shRNA. See Figure 4- figure supplement 3 for p53 knockdown efficiency. Note, there is 970 
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an increase in the number of calcein positive cells (decreased permeability) upon p53 971 
knockdown in cells harboring p53-psi or p53 exon-6 truncating mutations (n=3, p-value 972 
*<0.05, **<0.005 and ***<0.0005, unpaired t-test). H. The chart indicates the ratio of JC-973 
1 aggregate relative to monomer in the indicated cells after p53 knockdown with a p53 974 
shRNA lentiviral construct relative to scrambled shRNA. Note the increase in the number 975 
of J aggregates (increased mitochondrial polarization) upon p53 knockdown in cells 976 
harboring p53-psi or p53 exon-6 truncating mutations (n=3, p-value *<0.0005, 977 
**<0.00005 and ***<0.000005, unpaired t-test). 978 
 979 
Figure 5: CypD activity is required for phenotypes associated with TP53 exon-6 980 
truncating mutations. A. CypD is required for maintaining cells in a mesenchymal like 981 
state. The chart represents mRNA expression analysis of the indicated genes in A549 982 
(p53-WT), Hop62 (p53-psi), DMS114 (p53-R213*) and Calu-6 (R196*) cell lines after 983 
CypD knockdown. Cells harboring p53-psi or TP53 exon-6 nonsense mutations are 984 
indicated in blue. mRNA expression was quantified by SYBR-green-based RT-qPCR. 985 
Each bar is the average of 3 replicates and represents mRNA expression of the 986 
indicated gene relative to GAPDH (p-value, *<0.05, **<0.005 and ***<0.0005, unpaired t-987 
test). See Figure 5- figure supplement 1A for analysis in additional cell lines. B. CypD is 988 
required for the survival of cells harboring p53-psi splice or TP53 exon-6 truncating 989 
mutations. The graph represents cell survival curve of indicated cell lines when treated 990 
with CypD inhibitor C-9 for 120hrs. C. Crystal violet staining of the indicated cell lines 991 
upon CypD knockdown with two independent shRNAs. A scramble shRNA was used as 992 
negative control. The quantification of knockdown efficiency is provided in Figure 5- 993 
figure supplement 1B. D. The chart depicts the percentage of viable cells 8 days after 994 
infection with the indicated CypD shRNA constructs relative to scramble shRNA control. 995 
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Each bar represents the mean of 9 individual replicates (p-value *<0.0005 and 996 
**<0.00005, unpaired t-test). E. Workflow of the transplantable model system used in this 997 
study. A549 (p53-WT) and Calu-6 (p53 R196*) cells were transduced with an inducible 998 
CRISPR-Cas9 (DD-Cas9) targeting CypD (CypD g.131) and Renila (Ren g.208). Cells 999 
were transplanted sub-cutaneously in immune-deficient mice. When the tumors reached 1000 
an approximate size of 4-5 mm in diameter, mice were treated with Shield-1 (1 µg). 1001 
Tumor volume was determined at the indicated time points. See Supplementary File 5 1002 
for sgRNA sequences. F. The charts illustrate quantification of tumor volumes (mean ± 1003 
SD) in the indicated cohorts at given time points (n=4, p-value *<0.05, unpaired t-test). 1004 
Validation of CypD inactivation is provided in Figure 5- figure supplement 2. 1005 
  1006 
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Titles for Supplementary File: 1007 
 1008 
Supplementary File 1: List of tumor studies used for analysis of distribution of 1009 
Missense, Exon-6 and other truncations in TP53. 1010 
 1011 
Supplementary File 2: Values of p53 mRNA expression with different mutations 1012 
obtained from four different tumor types. 1013 
 1014 
Supplementary File 3: Number of tumor samples with indicated mutation types in 1015 
primary and metastatic colorectal carcinoma. 1016 
 1017 
Supplementary File 4: Sequence of sense strand of shRNAs used in this study. 1018 
  1019 
Supplementary File 5: Complimentary oligonucleotides used for cloning the indicated 1020 
sgRNAs. 1021 
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Figure 1- figure supplement 1.
Distribution of TP53 somatic mutations across multiple tumor types based on TCGA
and MSKCC data set analysis.
A. Pie chart shows distribution of indicated somatic mutations in TP53 based on TCGA data.
For more information, see supplementary file 1.
B. Pie chart shows distribution of indicated somatic mutations in TP53 based on MSK-
IMPACT data (Cheng et al., 2015).
AB
Figure 1- figure supplement 2.
Graphical summary of TP53 non-synonymous mutations in melanoma in indicated
studies.
Distribution of different type somatic mutations mapped across TP53 gene in melanoma (A) 
TCGA and (B) MSK-IMPACT. Circles are colored with respect to the corresponding 
mutation types as follows: Missense Mutations- green; Truncating Mutations (Nonsense, 
Nonstop, Frameshift deletion, Frameshift insertion, Splice site)-orange; Inframe Mutations 
(Inframe deletion, Inframe insertion). 
AFigure 1- figure supplement 3.
TP53 exon-6 truncating mutations are distributed at different frequency in different
tumors.
A. Fraction of TP53 exon-6 truncating mutations in the indicated tumor types.
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Figure 3- figure supplement 2. 
Schematic of the p53-WT or truncated forms expressed in the cell lines utilized in this study.
A. Cell lines harboring TP53 exon-6 truncating mutations or splicing mutations are indicated in 
blue.
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Figure 4- figure supplement 1. 
p53-psi molecularly resembled TP53 exon-6 truncating mutations. 
A. Schematic representation of normal splicing as well as alternative splicing event in TP53 generating p53-WT
and p53-psi as indicated. Lower panel schematic shows structural similarity between p53-psi protein and p53 
exon-6 truncations. Each exon in TP53 is indicated with Roman numerals. 
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